
zzso zzso zzso is a rare but potentially devastating event which can result in severe injuries including zzso and zzso zzso zzso serious joint damage and permanent zzso It can delay further scheduled chemotherapy and affect cancer treatment zzso zzso zzso is the only approved antidote for zzso in Europe zzso in the zzso and is administered by intravenous zzso Its efficacy has been demonstrated in clinical trials with zzso zzso with a zzso success rate (no need for surgical zzso allowing for immediate continuation of chemotherapy in zzso of zzso zzso events, mainly zzso zzso were rapidly zzso The objective of the study was to zzso in clinical practice, the efficacy and safety profile of zzso for zzso in different Belgian zzso 

A survey of zzso use was conducted in Belgium from 2007 to 2010 by using a questionnaire sent to 44 zzso 

Data were obtained for 41 cancer patients, zzso zzso had zzso from central zzso zzso zzso zzso due to zzso could be avoided in 26 out of 28 zzso from a central zzso access and in zzso zzso of the total population treated with zzso Planned chemotherapy was maintained in zzso zzso of zzso Eight adverse events were reported in four patients treated with zzso six events were assessed to be of common toxicity criteria grades 1-2 zzso zzso and arm zzso and two events zzso and zzso were assessed to be grade zzso 

These data are comparable with the data from previous clinical trials and confirm the efficacy and safety profile of zzso in clinical practice for the treatment of zzso zzso including zzso from central zzso zzso 

